title: Prostaglandin concentrations in ovine maternal and fetal tissues at late gestation.
abstract: Maternal and fetal sheep organs were measured for their concentrations of prostaglandins (PG) E2, F2 alpha, 13,14-dihydro-15-keto PGF2 alpha (PGFM), 6-keto PGF1 alpha (hydrolysis produce of PGI2), and 6-keto PGE1 (enzymatic product of PGI2) by radioimmunoassay at day 131 of pregnancy (0.90 gestation). It was observed that the concentrations of PGFM were greater (p less than 0.01) in maternal endometrium than in any other maternal tissue or any other PG measured in endometrium. The lowest concentrations of PG in maternal tissues were in the myometrium, while PGE2 and 6-keto PGF1 alpha were present in maternal lungs in high concentrations. Fetal prostaglandin concentrations were high in the chorioallantois, fetal portion of the cotyledons and amnion, while they were very low in the kidney, liver, and lung. Fetal lung concentrations were lower than maternal lung concentrations (p less than 0.01) for all PG measured. In fetal aorta and ductus arteriosus, 6-keto PGF1 alpha concentrations were significantly greater (p less than 0.05) than all other measured PG, while in umbilical artery and vein 6-keto PGF1 alpha levels were equal to PGE2 levels. 6-Keto PGE1 concentrations were consistently among the lowest in all tissues measured. These results suggest that the endometrium may serve as a metabolic barrier to PG diffusing from the chorioallantois to the myometrium, that the capacity of pulmonary tissue to produce PG may increase with age, that the fetal membranes and cotyledons may be one major source of circulating PG in the fetus, and that 6-keto PGF1 alpha is the major metabolite of PGI2 in ovine tissues.
authors.forename: D M
authors.initials: DM
authors.lastname: Olson
authors.forename: S J
authors.initials: SJ
authors.lastname: Lye
authors.forename: J R
authors.initials: JR
authors.lastname: Challis
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000378:metabolism; D000527:Alprostadil / Q000031:analogs & derivatives / Q000378:metabolism; D000818:Animals; D001808:Blood Vessels / Q000196:embryology / Q000378:metabolism; D002823:Chorion / Q000378:metabolism; D015237:Dinoprost / Q000031:analogs & derivatives; D015232:Dinoprostone; D004717:Endometrium / Q000378:metabolism; D005260:Female; D005333:Fetus / Q000378:metabolism*; D005865:Gestational Age; D007668:Kidney / Q000196:embryology / Q000378:metabolism; D008099:Liver / Q000196:embryology / Q000378:metabolism; D008168:Lung / Q000196:embryology / Q000378:metabolism; D009215:Myometrium / Q000378:metabolism; D011247:Pregnancy; D011453:Prostaglandins / Q000378:metabolism*; D011458:Prostaglandins E / Q000378:metabolism; D011460:Prostaglandins F / Q000378:metabolism; D012756:Sheep; D014599:Uterus / Q000378:metabolism*
chemical_list: D011453:Prostaglandins; D011458:Prostaglandins E; D011460:Prostaglandins F; C008228:15-keto-13,14-dihydroprostaglandin F2alpha; D015121:6-Ketoprostaglandin F1 alpha; C022950:6-ketoprostaglandin E1; D015237:Dinoprost; D000527:Alprostadil; D015232:Dinoprostone